ribosomal protein L29Genealiases: HIP · HUMRPL29 · L29 · RPL29P10 · RPL29_3_370 · eL29
Q-omics provides the consensus-scored RPL29 profile across patient tissues and cancer cell-line models. RPL29 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL29 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, RPL29 RNA expression shows 18,693 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRP, and THYM as cancer lineages where RPL29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL29 survival associations across molecular data types. RPL29 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL29 RNA expression–survival associations across cancer types. High RPL29 expression shows unfavorable associations in ACC, LIHC and UCEC, but favorable associations in UVM, BRCA and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL29 RNA expression.
This table summarizes RPL29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPL29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL29 shows lower tumor expression in HNSC and BRCA and higher tumor expression in KIRP, KIRC, LIHC and COAD. The KIRP box plot shows higher RPL29 RNA expression in tumor versus normal tissue (log2 FC = +0.929, t-test p < 0.001).
This table shows molecular features associated with RPL29 in patient tissues and cancer cell lines. In patient samples, RPL29 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
